Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Estradiol recalled?

Yes — there is an active recall. 23 ongoing FDA recalls mention Estradiol (295 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Estradiol. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Estradiol recalls on record

none so far in 2026; 295 on record, newest first
Class III · Low risk

Bekyree

Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-879-11 D-1055-2020
Class III · Low risk

Tri-Lo-Marzia

CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data.

Terminated Failed specification Lupin Pharmaceuticals Inc. NDC 68180-837-13 D-0790-2020
Class II · Moderate risk

Blisovi Fe 1.5/30

Failed Tablet/Capsule Specifications: Complaints related to crumbling of tablets when popped out of the blister pack.

Terminated Failed specification Lupin Pharmaceuticals Inc. NDC 68180-866-11 D-0638-2020
Class II · Moderate risk

Estradiol Vaginal Inserts USP

Defective Delivery System: complaints for difficulty in pushing the plunger of the applicator.

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-711-71 D-0156-2020
Class II · Moderate risk

Estradiol tablets

Presence of Foreign Tablets/Capsules: Estradiol 1 mg was found in a 100 count bottle of Estradiol 0.5 mg Tablets.

Terminated Particulate / foreign matter Epic Pharma, LLC NDC 42806-087-01 D-0135-2020
Class II · Moderate risk

Estradiol Vaginal Inserts USP 10 mcg

Defective Delivery System: Estradiol Vaginal Inserts USP plunger is not functioning properly.

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-711-71 D-1340-2019
Class II · Moderate risk

Fayosim (levonorgestrel and ethinyl estradiol)

Failed Impurities/Degradation Specifications: Out-of-specification results observed in related substance test (Any Other Individual Impurity and Total impurities) in Ethinyl Estradiol Tablets USP 0.01mg at 12 month long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-860-11 D-1057-2019
Class II · Moderate risk

Estradiol Vaginal Inserts

Defective Delivery System: Customer complaints of malfunctioning plunger of the applicator

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-711-71 D-0350-2019
Class II · Moderate risk

Estradiol Tablets

Presence of foreign tablet/capsule: A single foreign tablet was found in pharmacy dispensed bottle of 30 Estradiol 2 mg tablets.

Terminated Particulate / foreign matter Epic Pharma, LLC NDC 42806-089-01 D-0297-2019
Class II · Moderate risk

Ortho-Novum 7/7/7

Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

Terminated Labeling / mix-up Janssen Pharmaceuticals, Inc. NDC 50458-178-06 D-0218-2019
Class II · Moderate risk

Ortho-Novum 1/35

Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

Terminated Labeling / mix-up Janssen Pharmaceuticals, Inc. NDC 50458-176-28 D-0217-2019